– USA, MA – Upstream Bio, a clinical-stage biotech company advancing new therapies to treat inflammation, today announced the appointment of Dr. Marcella Ruddy (MD) to its Board of Directors.
“It is a pleasure to welcome Marcie, a highly experienced industry leader, to our Board of Directors. Her deep drug development and clinical expertise in asthma and other inflammation-driven diseases are invaluable as we advance our program and plan expansion into new indications to address unmet needs for patients. Marcie’s background is an important addition to our board and a key step toward diversifying the perspectives represented in our Board discussions,” said CEO, Sam Truex.
About Dr. Marcella Ruddy
Dr. Ruddy is the CMO of Tectonic Therapeutic. Dr. Ruddy has an extensive background in drug development and inflammation from her work as both a clinician and the previous Head of Clinical Development for the Immunology/Inflammation therapeutic area at Regeneron Pharmaceuticals, where she was instrumental in driving the development of dupilumab across multiple indications.
Dr. Ruddy will transition from her previous role as a clinical advisor to Upstream to a Board member, continuing to provide valuable strategic input regarding the development of UPB-101. UPB-101 is a novel, recombinant fully human immunoglobulin G1 monoclonal antibody that binds to the human thymic stromal lymphopoietin receptor to inhibit signaling. UPB-101 is currently in a Phase 1b multiple ascending dose study in asthma patients.
“I am delighted to join the Board at this exciting time in the Company’s evolution,” said Dr. Ruddy. “The accomplishments of the team to date have been noteworthy and I’m looking forward to continuing to be part of the progress at Upstream Bio. The company is well positioned to execute its mission to stop inflammation at its source via TSLP receptor inhibition.”
Dr. Ruddy has over 18 years of drug development experience. Before Regeneron, Dr. Ruddy held clinical leadership positions at Alnylam, EMD Serono, and Merck Research labs where she oversaw the early clinical development of programs across multiple therapeutic areas including inflammation, respiratory, muscle, metabolic, and rare diseases. She is a board-certified pulmonologist and held a staff position in the Pulmonary Unit at Massachusetts General Hospital/Harvard Medical School where she founded and directed the Adult Cystic Fibrosis Program. Earlier in her career, she completed her Internal Medicine Residency and Pulmonary Critical Care Fellowship training at Harvard Medical School and associated medical centers. Dr. Ruddy holds an AB (Bachelor of Arts) from Princeton University and a Doctor of Medicine from Washington University, St Louis.
About Upstream Bio
At Upstream Bio we strive to reach the source of inflammation and conquer it. Our lead program, UPB-101, is a clinical-stage monoclonal antibody that inhibits the TSLP receptor. TSLP is a validated target positioned upstream of multiple signaling cascades that affect a variety of immune cells pivotal to common and rare diseases. We are leveraging our diverse roots and the team’s substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones.
For more information: https://www.upstreambio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
